Assessing the role of IL-35 in colorectal cancer progression and prognosis

International Journal of Clinical and Experimental Pathology

Volumn 6, Issue 9, 2013, Pages 1806-1816

  Zeng, Jin Cheng ^a,b   Zhang, Zhi ^a   Li, Tian Yu ^a   Liang, Yan Fang ^c   Wang, Hong Mei ^a   Bao, Jing Jing ^b   Zhang, Jun Ai ^b   Wang, Wan Dang ^a   Xiang, Wen Yu ^a   Kong, Bin ^b   Wang, Zhi Yong ^a,b   Wu, Bin Hua ^b   Chen, Xiao Dong ^a   He, Long ^d   Zhang, Shu ^d   Wang, Cong Yi ^a,b,d   Xu, Jun Fa ^a,b  

^a GUANGDONG MEDICAL UNIVERSITY   (China)

^b Key Laboratory for Medical Molecular Diagnostics of Guangdong Province   (China)

^c Taiping People's Hospital of Dongguan)   (China)

^d HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Colorectal cancer; EBI3; IL 12p35; Interleukin 35; Regulatory T cell

Indexed keywords

CDCA5 PROTEIN, HUMAN; CELL CYCLE PROTEIN; EBI3 PROTEIN, HUMAN; INTERLEUKIN 35, HUMAN; INTERLEUKIN DERIVATIVE; INTERLEUKIN-35, HUMAN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD; CANCER GRADING; CANCER STAGING; CASE CONTROL STUDY; COLON RESECTION; COLORECTAL CANCER; COLORECTAL TUMOR; DISEASE COURSE; EBI3; FEMALE; HUMAN; IL-12P35; IMMUNOLOGY; INTERLEUKIN-35; MALE; METABOLISM; MIDDLE AGED; NEUTROPHIL CHEMOTAXIS; PATHOLOGY; REGULATORY T LYMPHOCYTE; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; YOUNG ADULT;

COLORECTAL CANCER; EBI3; IL-12P35; INTERLEUKIN-35; REGULATORY T CELL;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; CASE-CONTROL STUDIES; CELL CYCLE PROTEINS; CHEMOTAXIS, LEUKOCYTE; COLECTOMY; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; INTERLEUKINS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; T-LYMPHOCYTES, REGULATORY; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR MICROENVIRONMENT; YOUNG ADULT;

EID: 84885362636     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM, Cross R, Sehy D, Blumberg RS and Vignali DA. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007; 450: 566-569.
2. Devergne O, Birkenbach M and Kieff E. Epstein-Barr virus-induced gene 3 and the p35 subunit of interleukin 12 form a novel heterodimeric hematopoietin. Proc Natl Acad Sci U S A 1997; 94: 12041-12046.
3. Devergne O, Hummel M, Koeppen H, Le Beau MM, Nathanson EC, Kieff E and Birkenbach M. A novel interleukin-12 p40-related protein induced by latent Epstein-Barr virus infection in B lymphocytes. J Virol 1996; 70: 1143-1153.
4. Niedbala W, Wei XQ, Cai B, Hueber AJ, Leung BP, McInnes IB and Liew FY. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur J Immunol 2007; 37: 3021-3029.
5. Collison LW, Delgoffe GM, Guy CS, Vignali KM, Chaturvedi V, Fairweather D, Satoskar AR, Garcia KC, Hunter CA, Drake CG, Murray PJ and Vignali DA. The composition and signaling of the IL-35 receptor are unconventional. Nat Immunol 2012; 13: 290-299.
6. Collison LW, Pillai MR, Chaturvedi V and Vignali DA. Regulatory T cell suppression is potentiated by target T cells in a cell contact, IL-35- and IL-10-dependent manner. J Immunol 2009; 182: 6121-6128.
7. Huang CH, Loo EX, Kuo IC, Soh GH, Goh DL, Lee BW and Chua KY. Airway inflammation and IgE production induced by dust mite allergen-specific memory/effector Th2 cell line can be effectively attenuated by IL-35. J Immunol 2011; 187: 462-471.
8. Whitehead GS, Wilson RH, Nakano K, Burch LH, Nakano H and Cook DN. IL-35 production by inducible costimulator (ICOS)-positive regulatory T cells reverses established IL-17-dependent allergic airways disease. J Allergy Clin Immunol 2012; 129: 207-215, e201-205.
9. Wirtz S, Billmeier U, McHedlidze T, Blumberg RS and Neurath MF. Interleukin-35 mediates mucosal immune responses that protect against T-cell-dependent colitis. Gastroenterology 2011; 141: 1875-1886.
10. Bardel E, Larousserie F, Charlot-Rabiega P, Coulomb-L'Hermine A and Devergne O. Human CD4+ CD25+ Foxp3+ regulatory T cells do not constitutively express IL-35. J Immunol 2008; 181: 6898-6905.
11. Bettini M, Castellaw AH, Lennon GP, Burton AR and Vignali DA. Prevention of autoimmune diabetes by ectopic pancreatic beta-cell expression of interleukin-35. Diabetes 2012; 61: 1519-1526.
12. Chaturvedi V, Collison LW, Guy CS, Workman CJ and Vignali DA. Cutting edge: Human regulatory T cells require IL-35 to mediate suppression and infectious tolerance. J Immunol 2011; 186: 6661-6666.
13. Collison LW, Chaturvedi V, Henderson AL, Giacomin PR, Guy C, Bankoti J, Finkelstein D, Forbes K, Workman CJ, Brown SA, Rehg JE, Jones ML, Ni HT, Artis D, Turk MJ and Vignali DA. IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol 2010; 11: 1093-1101.
14. Kochetkova I, Golden S, Holderness K, Callis G and Pascual DW. IL-35 stimulation of CD39+ regulatory T cells confers protection against collagen II-induced arthritis via the production of IL-10. J Immunol 2010; 184: 7144-7153.
15. Li X, Mai J, Virtue A, Yin Y, Gong R, Sha X, Gutchigian S, Frisch A, Hodge I, Jiang X, Wang H and Yang XF. IL-35 is a novel responsive anti-inflammatory cytokine--a new system of categorizing anti-inflammatory cytokines. PLoS One 2012; 7: e33628.
16. Devergne O, Coulomb-L'Hermine A, Capel F, Moussa M and Capron F. Expression of Epstein-Barr virus-induced gene 3, an interleukin-12 p40-related molecule, throughout human pregnancy: involvement of syncytiotro-phoblasts and extravillous trophoblasts. Am J Pathol 2001; 159: 1763-1776.
17. Niedobitek G, Pazolt D, Teichmann M and Devergne O. Frequent expression of the Epstein-Barr virus (EBV)-induced gene, EBI3, an IL-12 p40-related cytokine, in Hodgkin and Reed-Sternberg cells. J Pathol 2002; 198: 310-316.
18. Poleganov MA, Bachmann M, Pfeilschifter J and Muhl H. Genome-wide analysis displays marked induction of EBI3/IL-27B in IL-18-activated AML-derived KG1 cells: critical role of two kappaB binding sites in the human EBI3 promotor. Mol Immunol 2008; 45: 2869-2880.
19. Long J, Zhang X, Wen M, Kong Q, Lv Z, An Y and Wei XQ. IL-35 over-expression increases apoptosis sensitivity and suppresses cell growth in human cancer cells. Biochem Biophys Res Commun 2013; 430: 364-369.
20. Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G, Drebin JA, Strasberg SM, Eberlein TJ, Goedegebuure PS and Linehan DC. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002; 169: 2756-2761.
21. Wolf D, Wolf AM, Rumpold H, Fiegl H, Zeimet AG, Muller-Holzner E, Deibl M, Gastl G, Gunsilius E and Marth C. The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res 2005; 11: 8326-8331.
22. Nishino R, Takano A, Oshita H, Ishikawa N, Akiyama H, Ito H, Nakayama H, Miyagi Y, Tsuchiya E, Kohno N, Nakamura Y and Daigo Y. Identification of Epstein-Barr virus-induced gene 3 as a novel serum and tissue biomarker and a therapeutic target for lung cancer. Clin Cancer Res 2011; 17: 6272-6286.
23. Larousserie F, Bardel E, Pflanz S, Arnulf B, Lome-Maldonado C, Hermine O, Bregeaud L, Perennec M, Brousse N, Kastelein R and Devergne O. Analysis of interleukin-27 (EBI3/p28) expression in Epstein-Barr virus- and human T-cell leukemia virus type 1-associated lymphomas: heterogeneous expression of EBI3 subunit by tumoral cells. Am J Pathol 2005; 166: 1217-1228.
24. Wang Z, Liu JQ, Liu Z, Shen R, Zhang G, Xu J, Basu S, Feng Y and Bai XF. Tumor-derived IL-35 promotes tumor growth by enhancing myeloid cell accumulation and angiogenesis. J Immunol 2013; 190: 2415-2423.
25. Zhang S, Lv JW, Yang P, Yu Q, Pang J, Wang Z, Guo H, Liu S, Hu J, Li J, Leng J, Huang Y, Ye Z and Wang CY. Loss of dicer exacerbates cyclophosphamide-induced bladder overactivity by enhancing purinergic signaling. Am J Pathol 2012; 181: 937-946.
26. Yang P, Zhang Y, Xu J, Zhang S, Yu Q, Pang J, Rao X, Kuczma M, Marrero MB, Fulton D, Kraj P, Su Y and Wang CY. SUMO1 regulates endothelial function by modulating the overall signals in favor of angiogenesis and homeostatic responses. Am J Transl Res 2013; 5: 427-440.
27. Rao X, Zhong J, Zhang S, Zhang Y, Yu Q, Yang P, Wang MH, Fulton DJ, Shi H, Dong Z, Wang D and Wang CY. Loss of methyl-CpG-binding domain protein 2 enhances endothelial angiogenesis and protects mice against hind-limb ischemic injury. Circulation 2011; 123: 2964-2974.
28. Michalski CW, Oti FE, Erkan M, Sauliunaite D, Bergmann F, Pacher P, Batkai S, Muller MW, Giese NA, Friess H and Kleeff J. Cannabinoids in pancreatic cancer: correlation with survival and pain. Int J Cancer 2008; 122: 742-750.
29. Zhong J, Yang P, Muta K, Dong R, Marrero M, Gong F and Wang CY. Loss of Jak2 selectively suppresses DC-mediated innate immune response and protects mice from lethal dose of LPS-induced septic shock. PLoS One 2010; 5: e9593.
30. Chen XQ, Liu XF, Liu WH, Guo W, Yu Q and Wang CY. Comparative analysis of dendritic cell numbers and subsets between smoking and control subjects in the peripheral blood. Int J Clin Exp Pathol 2013; 6: 290-296.
31. Olson BM, Jankowska-Gan E, Becker JT, Vignali DA, Burlingham WJ and McNeel DG. Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockade. J Immunol 2012; 189: 5590-5601.